Comparison between cryotherapy and topical zinc sulfate with cryotherapy and placebo in common wart treatment
Phase 3
- Conditions
- verruca vulgaris.viral warts
- Registration Number
- IRCT2017100936660N1
- Lead Sponsor
- Vice Chancellor for Research, Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
inclusion criteria:
consent to participate; verruca vulgaris patients with minimum of one lesion that has minimum diameter of 6 millimeter
exclusion criteria:
lesions on face, genitalia and periungual; patients under 12 and above 50 years; immune suppression; pregnancy and lactating; patients who has received any treatment
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Size of lesion. Timepoint: before intervention, 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: scaling with ruler( in millimeter).;Treatment sessions number. Timepoint: every other week until complete resolusion or up to 3 months. Method of measurement: counting.
- Secondary Outcome Measures
Name Time Method Hyperpigmentation. Timepoint: 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: inspection.;Hypopigmentation. Timepoint: 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: inspection.;Blister. Timepoint: 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: inspection.;Pain. Timepoint: 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: questionnaire.;Pruritus. Timepoint: 2, 4, 6, 8, 10 and 12 weeks after intervention. Method of measurement: questionnaire.